TOMI Environmental Solutions, Inc. (TOMZ) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed financial performance with a significant revenue decline and a shift from operating income to loss. While there is optimism in strategic partnerships and market expansion, the Q&A section highlights uncertainties, especially regarding FDA approval impacts and international sales efforts. The lack of specific guidance and vague responses to key questions further dampen sentiment. Despite some positive long-term prospects, immediate financial challenges and unclear management responses suggest a negative short-term market reaction.
Key Financial Performance
Revenue for Q3 2025 $2 million, a 24% decrease from $2.5 million in Q3 2024. The decline was primarily due to a timing reduction in iHP services sales from a key customer who reorganized its operations. This impact is expected to be temporary.
Sequential Revenue Growth 95% increase from Q2 2025 to Q3 2025, driven by expanding recurring revenue streams and deeper customer engagement.
Recurring BIT Solution Sales Increased 21% year-to-date compared to 2024, attributed to a focus on existing customer base, implementation, usage, and tailored protocol development.
Sales Order Backlog $0.9 million at the end of Q3 2025, growing to $1.3 million by October 31, 2025. Approximately $3 million in pending SteraMist Integration Contracts expected to close before year-end.
Gross Profit Margins 61% for Q3 2025, consistent with the same period in 2024, reflecting resilience in product mix and disciplined cost management.
Operating Loss for Q3 2025 Approximately $320,000, compared to an operating income of $149,000 in Q3 2024.
Net Loss for Q3 2025 Approximately $450,000 or $0.02 per share, compared to a net income of $58,000 in Q3 2024.
Cash and Cash Equivalents Approximately $190,000 as of September 30, 2025.
Working Capital $2.5 million as of September 30, 2025.
Shareholder Equity $2.2 million as of September 30, 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Recurring revenue growth: Recurring BIT Solution sales have risen 21% year-to-date, contributing significantly to the company's revenue growth.
Capital equipment sales: Increased capital purchases of mobile equipment by service provider partners, including industry leaders and smaller players.
New product adoption: SteraMist iHP technology continues to gain industry recognition and adoption, including being named the disinfection and decontamination products company of the year 2025.
Regulatory developments: FDA's broadened approval of hydrogen peroxide opens new markets in agriculture, food processing, and environmental biosafety.
International expansion: Active pipeline surpasses $15 million, including domestic and international customers, with $3 million in pending SteraMist Integration Contracts expected to close before year-end.
New partnerships: Collaboration with Nestle to establish SteraMist technology as a global standard across their nutritional facilities worldwide.
Operational efficiency: Gross profit margins remain strong at 61%, reflecting disciplined cost management and a resilient product mix.
Customer engagement: Focus on tailored protocol development and training programs to enhance customer implementation and usage.
Sales strategy: Sales backlog grew from $0.9 million to $1.3 million by October 31, with a strong pipeline of $15 million.
Strategic partnerships: Entered into an equity purchase agreement with Hudson Global Ventures for up to $20 million in common stock over 24 months to fund growth initiatives.
Market positioning: Positioning SteraMist iHP technology as a benchmark for sterile environments in pharmaceutical and other industries.
Future focus: Sharpening focus on biosecurity advancements, automation integrations, and sustainable agricultural opportunities heading into 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: The company experienced a 24% decrease in revenue in Q3 2025 compared to Q3 2024, primarily due to a temporary reduction in iHP service sales from a key customer who reorganized its operations.
Operating Loss: The company reported an operating loss of approximately $320,000 in Q3 2025, compared to an operating income of $149,000 in the same period last year.
Net Loss: The net loss for Q3 2025 was approximately $450,000, compared to a net income of $58,000 in Q3 2024.
Cash Position: As of September 30, 2025, the company had cash and cash equivalents of approximately $190,000, which may limit its ability to fund operations and growth initiatives without additional financing.
Extended CES Timelines: The custom-engineered system (CES) has extended timelines from initial interest to full commissioning, which can be expensive and delay revenue realization.
Regulatory and Market Risks: While regulatory changes like FDA approval of hydrogen peroxide open new markets, they also require significant investment in R&D and market expansion, which could strain resources.
Supply Chain Vulnerabilities: The company highlighted the need to address supply chain vulnerabilities as part of its biosecurity advancements, indicating potential risks in maintaining consistent operations.
Dependence on Key Customers: The temporary reduction in service sales from a key customer underscores the risk of over-reliance on a limited number of major clients.
Competitive Pressures: The company operates in highly competitive markets, including life sciences, food safety, and health care, which may impact its ability to maintain or grow market share.
Capital Requirements: The company entered into an equity purchase agreement to raise up to $20 million, indicating a need for additional capital to fund operations, R&D, and market expansion.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company anticipates continued growth in recurring BIT Solution sales, capital equipment sales, and custom integrations. The active pipeline is valued at over $15 million, with $3 million in pending SteraMist Integration Contracts expected to close before year-end 2025.
Market Expansion: TOMI is focusing on biosecurity advancements, scaling automation integrations, and exploring opportunities in sustainable agriculture and public infrastructure. The company is also targeting the food safety market, leveraging FDA regulatory changes to expand applications of SteraMist.
Strategic Partnerships: The company is strengthening relationships with major pharmaceutical companies like Merck, Eli Lilly, and AstraZeneca, and expanding its presence in the academic and healthcare sectors. It is also pursuing collaborations in the cannabis market and food safety industry.
Product Development: TOMI is prioritizing the development of hybrid and SIS products for faster integration and revenue realization. The company is also enhancing training programs and certifications to drive product adoption and customer engagement.
Financial Strategy: The company has entered into an equity purchase agreement with Hudson Global Ventures, allowing access to up to $20 million in capital over 24 months to fund growth initiatives, R&D, and market expansion.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are your sales and marketing efforts towards the FDA approval for hydrogen peroxide usage, and have you identified initial targeted customers?
A:The approval is relatively new, and the food industry could be a key marketing vertical. However, it is too early to specify sales and targeted customers. Many food companies are not yet aware of the change, but the technology is expected to be a game changer.
Q:Should we expect operating expenses and gross margins to improve financially?
A:Operating expenses are expected to increase but will be positive in relation to revenue. Gross margins may see a slight improvement of 1-2%, holding around 60%. Operating expenses as a percentage of total revenue will not significantly increase.
Q:What kind of sales effort is in place internationally, particularly in Morocco and Africa?
A:The company has distributors in some countries and global partners implementing the technology in their facilities. These partners have a global footprint and are increasing their demand for SteraMist.
Q:Do you have visibility on solution sales in the coming quarters?
A:There is no specific visibility on solution sales. However, recurring sales are expected to increase by the end of the fourth quarter as more technology is deployed and sales strategies are enhanced.
Q:Are there any updates on servicing the military and defense markets?
A:The company is working with a key site to replace formaldehyde, conducting studies with positive results. However, no significant developments are expected before 2026.
Q:Any updates on the CAR T-cell disinfection business?
A:There are no updates on the CAR T-cell disinfection business.
Q:What are the expectations for the rollout by the top major service provider companies in healthcare mold remediation?
A:The onboarding of Steri-Clean, T.A.C.T., and another group has been significant. These companies are focused on biohazard and mycotoxin remediation, and the company expects a dramatic shift in service providership with aggressive training and support.
Q:Are there any plans to penetrate the disinfection market for data centers?
A:The company is interested in the data center market but currently lacks the employees to focus on it. Expanding the sales team is a priority to address this market.
Q:How is the company increasing awareness for the FDA's broadening of hydrogen peroxide use in the food industry?
A:The company is using social media and educational efforts to increase awareness. They are targeting companies in their database and those with past issues, focusing on creating protocols under the new FDA guidelines.
Q:Any progress in using SteraMist to replace ethylene oxide in medical instrument sterilization?
A:The company is prioritizing partnerships in device manufacturing to integrate iHP technology for decontaminating devices and machinery in the medical and food industries.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or lacked clarity on the following questions: 1. Sales and marketing efforts for FDA-approved hydrogen peroxide usage lacked specific details on targeted customers. 2. Visibility on solution sales in the coming quarters was vague, with no specific data provided. 3. Updates on the military and defense markets were limited, with no concrete developments expected before 2026. 4. Plans for penetrating the data center disinfection market were unclear, citing a lack of employees without further details on timelines or strategies.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AALAS
Chief Executive
Chief Financial
Coast
SteraMist technology
Steri
TACT
University
activity
adoption
approach
automation
breakthrough
capability
chain
control
core
custom integration
delivery
efficacy
engagement
equipment sale
health care
hydrogen peroxide
implementation
income period
installation
leader
mold
month
player
point
processing
production
resilience
roster
sector
standard
stream
theme momentum
traction
TOMZ Transcript
TOMI Environmental Solutions, Inc. (TOMZ) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call showed a strong financial performance with a 15% revenue increase, improved gross margin, and positive net income, indicating a turnaround. Despite risks mentioned in forward-looking statements, the financial health and operational efficiency improvements are positive indicators. The lack of strategic initiatives and operational updates is a downside, but the overall financial results and improved cash flow support a positive sentiment.
TOMI Environmental Solutions, Inc. (TOMZ) Q4 2025 Earnings Call Transcript
Positive3-31
The company reported strong financial performance with a 25% YoY revenue increase, improved gross margins, and a 33% rise in net income, indicating robust demand and operational efficiency. Positive cash flow growth further supports this strength. Despite no strategic or risk discussions, the financial metrics alone suggest a strong positive sentiment. With no negative insights from the Q&A, the stock is likely to experience a strong positive movement over the next two weeks, especially if it is a small-cap stock.
TOMI Environmental Solutions, Inc. (TOMZ) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call reveals a mixed financial performance with a significant revenue decline and a shift from operating income to loss. While there is optimism in strategic partnerships and market expansion, the Q&A section highlights uncertainties, especially regarding FDA approval impacts and international sales efforts. The lack of specific guidance and vague responses to key questions further dampen sentiment. Despite some positive long-term prospects, immediate financial challenges and unclear management responses suggest a negative short-term market reaction.
TOMI Environmental Solutions, Inc. (TOMZ) Q2 2025 Earnings Call Transcript
Unknown8-19
Despite positive developments like high solution sales margins and potential opportunities in pharma manufacturing, the earnings call reveals significant challenges. A 66% revenue decline, increased operating losses, and regulatory hurdles dampen optimism. The Q&A highlights deferred CapEx projects and vague management responses, adding uncertainty. While there are growth prospects, the lack of concrete timelines and financial guidance tempers expectations. Overall, the mixed signals suggest a neutral stock price movement.
TOMZ Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
